24-NHL-38-AT-PMC (ALLO-501A-202): A Randomized, Open-Label Study Evaluating The Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants With Minimal Residual Disease After Response to First Line Therapy for Large B-Cell Lymphoma (ALPHA 3)